| AIDS Treatment News
IAS Buenos Aires Conference:
Medscape CME Summaries
On July 31 the Medscape Web site, named the official
provider of online coverage for the new International AIDS
Society conference which took place July 8-11, 2001 in
Buenos Aires, Argentina, released three Continuing Medical
Education programs for medical professionals. Anyone can
use them for a review of current knowledge in some of the
major areas of HIV treatment. These programs will remain
online for one year.
The Medscape site requires a one-time registration, but it
is cost-free.
Here we list the titles of the programs and the articles
required for CME credit in each one. Each program also has
several other articles available which are not listed here.
I. Current Patient Management:
New Light Through Old Windows: Fine-tuning the Use of
Approved Antiretrovirals, by Graeme Moyle, M.D., M.B.B.S.
Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics:
The Continuing Evolution of Pharmacologic Issues in HIV
Disease, by Stephen Becker, M.D.
Update on Antiretroviral Drug Resistance, by Daniel R.
Kuritzkes, M.D.
Management of HIV-Infected Women and Mother-to-Child HIV
Transmission, by Alexandra M. Levine, M.D.
II. Novel Therapeutic Strategies
HIV Entry -- From Molecular Insights to Specific
Inhibitors, by William A. O'Brien, M.D., M.S.
Investigational Antiretrovirals in Existing Classes, Mike
Youle, M.B.B.S.
Strategies for Immune Reconstitution in HIV Disease, by
Ronald T. Mitsuyasu, M.D.
Insights From Basic Science: Implications for HIV
Treatment and Prevention, Mark A. Wainberg, Ph.D.
III. Complications of HIV Disease
Opportunistic Infections: Still a World-Wide Problem,
Even in the HAART Era, by Henry Masur, M.D.
New Developments in AIDS-Related Hematology and Oncology,
by Alexandra M. Levine, M.D.
Adverse Effects of Antiretroviral Therapy: More Noise,
Less Clarity?, by William G. Powderly, M.D.
FDA: New Email List on HIV/AIDS
|
The U.S. Food and Drug Administration has started an email
list anyone can join, to provide AIDS-related information
from the Agency. The official announcement, below, gives
details.
Note: The sign-up process shows users confusing options --
but they can be ignored. Just stay with the defaults
provided, unless you know you want something else.
"An e-mail list has been established by the Division of
Antiviral Drug Products (Center for Drug Evaluation and
Research) and the Office of Special Health Issues (Office
of the Commissioner) of the Food and Drug Administration
(FDA) to provide updates on safety and regulatory issues
related to HIV/AIDS products.
|
Related Articles from the
GayToday Archive:
AIDS Treatment Fact Sheets: Interview with Bob Munk
Outlook 2000: AIDS Treatments
The Politics of Life & Death:Global Responses to HIV & AIDS
Related Sites:
AIDS Treatment News
Food & Drug Administration
GayToday does not endorse related sites.
|
"The purpose of this e-mail list is to give patients,
industry, academia, other government agencies and other
interested parties one source for FDA HIV/AIDS related
information. Information such as product approvals,
significant labeling changes, safety warnings, notices of
upcoming public meetings and alerts to proposed regulatory
guidances for comment will be distributed through this e-
mail list.
"To join the e-mail list, please go to
http://list.nih.gov/archives/fda-hiv-aids.html. Your name
and e-mail address is considered confidential and will not
be released.
"If you are interested in regulatory guidance and requirements for blood safety,
you should also register for the FDA's Center for Biologics Evaluation
and Research e-mail list at http://www.fda.gov/cber/pubinfo/elists.htm
"The HIV/AIDS e-mail list is not intended or designed to
accept comments or input, but merely to disseminate
important HIV/AIDS-related information and alert interested
parties about HIV/AIDS related issues for public comment.
"Information will be distributed through this e-mail list
as it becomes available, rather than on a regularly
scheduled basis.
"For additional information about the FDA HIV/AIDS e-mail list please contact
the Office of Special Health Issues at oshi@oc.fda.gov."
AIDS Treatment
News
Published twice monthly
Subscription and Editorial Office:
1233 Locust St., 5th
floor
Philadelphia, PA 19107
800/TREAT-1-2 toll-free
email:
aidsnews@critpath.org
useful
links: http://www.aidsnews.org/
Editor and Publisher: John S. James
Associate
Editor: Tadd T. Tobias
Statement of Purpose:
AIDS Treatment News reports on experimental and
standard treatments, especially those available now. We interview
physicians, scientists, other health professionals, and persons with AIDS
or HIV; we also collect information from meetings and conferences, medical
journals, and computer databases. Long-term survivors have usually tried
many different treatments, and found combinations that work for them.
AIDS Treatment News does not recommend particular therapies,
but seeks to increase the options available.
AIDS Treatment News is published 24 times per year,
on the first and third Friday of every month, and print copies are sent by
first class mail. Email is available (see below). Back issues are
available at http://www.aidsnews.org/
To subscribe, you can call 800-TREAT-1-2 or 415-255-0588:
Businesses, Institutions, Professionals: $325/year. Early email
available (see below).
Nonprofit organizations: $150/year.
Individuals: $140/year, or $80 for six months. If you cannot afford a
subscription, please write or call about our sliding scale.
Outside North, Central, or South America, add airmail postage:
$20/year, $10 for six months.
Bulk rates and multiple discount subscriptions are available; contact
our office for details.
Payment can be by check, VISA, Mastercard, American Express, bank
draft, purchase order, international postal money order, or travelers
checks.
Early email: Business, nonprofit and full-rate individual
subscribers can receive an early copy by email, before the issue is
printed--in addition to their regular copy, at no extra charge. It's OK to
direct the email copy to someone else. Call our office to add email to
your subscription.
Free email: Free delivery for individuals (delayed one
week). To subscribe, send a blank email to: aidsnews-subscribe@egroups.com
ISSN # 1052-4207
Copyright 2001 by John S. James.
|
